{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:18:12Z","timestamp":1790039892281,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tianjin Health Research Project","award":["TJWJ 2022QN008"],"award-info":[{"award-number":["TJWJ 2022QN008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10072-025-08488-x","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:10:22Z","timestamp":1759378222000},"page":"6679-6685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elevated levels of cerebrospinal fluid CHIT1 correlate with disease activity in neuromyelitis optica spectrum disorder"],"prefix":"10.1007","volume":"46","author":[{"given":"Hao","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhe","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7135-4013","authenticated-orcid":false,"given":"Li-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"8488_CR1","doi-asserted-by":"publisher","first-page":"460825","DOI":"10.1155\/2012\/460825","volume":"2012","author":"J Oh","year":"2012","unstructured":"Oh J, Levy M (2012) Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012:460825. https:\/\/doi.org\/10.1155\/2012\/460825","journal-title":"Neurol Res Int"},{"issue":"2","key":"8488_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"4","key":"8488_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","volume":"92","author":"BG Weinshenker","year":"2017","unstructured":"Weinshenker BG, Wingerchuk DM (2017) Neuromyelitis spectrum disorders. Mayo Clin Proc 92(4):663\u2013679. https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.014","journal-title":"Mayo Clin Proc"},{"key":"8488_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I et al (2020) Epidemiology of neuromyelitis Optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501. https:\/\/doi.org\/10.3389\/fneur.2020.00501","journal-title":"Front Neurol"},{"issue":"10206","key":"8488_CR5","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"B Cree","year":"2019","unstructured":"Cree B, Bennett JL, Kim HJ et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (n-momentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394(10206):1352\u20131363. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3","journal-title":"Lancet"},{"key":"8488_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-94-024-1057-0_16","volume":"969","author":"L Tradtrantip","year":"2017","unstructured":"Tradtrantip L, Jin BJ, Yao X, Anderson MO, Verkman AS (2017) Aquaporin-targeted therapeutics: state-of-the-field. Adv Exp Med Biol 969:239\u2013250. https:\/\/doi.org\/10.1007\/978-94-024-1057-0_16","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"8488_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41582-019-0184-2","volume":"15","author":"AF Lloyd","year":"2019","unstructured":"Lloyd AF, Miron VE (2019) The pro-remyelination properties of microglia in the central nervous system. Nat Rev Neurol 15(8):447\u2013458. https:\/\/doi.org\/10.1038\/s41582-019-0184-2","journal-title":"Nat Rev Neurol"},{"key":"8488_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105290","volume":"152","author":"S Yang","year":"2021","unstructured":"Yang S, Qin C, Hu ZW et al (2021) Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system. Neurobiol Dis 152:105290. https:\/\/doi.org\/10.1016\/j.nbd.2021.105290","journal-title":"Neurobiol Dis"},{"issue":"1","key":"8488_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/brain\/awad321","volume":"147","author":"C Qin","year":"2024","unstructured":"Qin C, Chen M, Dong MH et al (2024) Soluble trem2 triggers microglial dysfunction in neuromyelitis Optica spectrum disorders. Brain 147(1):163\u2013176. https:\/\/doi.org\/10.1093\/brain\/awad321","journal-title":"Brain"},{"issue":"4","key":"8488_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3988\/jcn.2020.16.4.562","volume":"16","author":"J Jang","year":"2020","unstructured":"Jang J, Nam Y, Choi Y et al (2020) Paramagnetic rims in multiple sclerosis and neuromyelitis Optica spectrum disorder: a quantitative susceptibility mapping study with 3-T MRI. J Clin Neurol 16(4):562\u2013572. https:\/\/doi.org\/10.3988\/jcn.2020.16.4.562","journal-title":"J Clin Neurol"},{"issue":"10","key":"8488_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jnen\/nlab083","volume":"80","author":"JW Prineas","year":"2021","unstructured":"Prineas JW, Parratt J (2021) Multiple sclerosis: microglia, monocytes, and macrophage-mediated demyelination. J Neuropathol Exp Neurol 80(10):975\u2013996. https:\/\/doi.org\/10.1093\/jnen\/nlab083","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"8488_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pathophys.2018.02.005","volume":"25","author":"S Ziatabar","year":"2018","unstructured":"Ziatabar S, Zepf J, Rich S, Danielson BT, Bollyky PI, Stern R (2018) Chitin, chitinases, and chitin lectins: emerging roles in human pathophysiology. Pathophysiology 25(4):253\u2013262. https:\/\/doi.org\/10.1016\/j.pathophys.2018.02.005","journal-title":"Pathophysiology"},{"issue":"3","key":"8488_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","volume":"89","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Verde F, Fang L et al (2018) Chitotriosidase (chit1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry 89(3):239\u2013247. https:\/\/doi.org\/10.1136\/jnnp-2017-317138","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"8488_CR14","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2014.2423","volume":"58","author":"M Di Rosa","year":"2014","unstructured":"Di Rosa M, Szychlinska MA, Tibullo D, Malaguarnera L, Musumeci G (2014) Expression of chi3l1 and chit1 in osteoarthritic rat cartilage model. A morphological study. Eur J Histochem 58(3):2423. https:\/\/doi.org\/10.4081\/ejh.2014.2423","journal-title":"Eur J Histochem"},{"issue":"11","key":"8488_CR15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/intimm\/dxh328","volume":"17","author":"M van Eijk","year":"2005","unstructured":"van Eijk M, van Roomen CP, Renkema GH et al (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17(11):1505\u20131512. https:\/\/doi.org\/10.1093\/intimm\/dxh328","journal-title":"Int Immunol"},{"key":"8488_CR16","doi-asserted-by":"publisher","unstructured":"Chang D, Sharma L, Dela CC (2020) Chitotriosidase: a marker and modulator of lung disease. Eur Respir Rev 29(156). https:\/\/doi.org\/10.1183\/16000617.0143-2019","DOI":"10.1183\/16000617.0143-2019"},{"issue":"9","key":"8488_CR17","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.55563\/clinexprheumatol\/hrjqdm","volume":"41","author":"D Masic","year":"2023","unstructured":"Masic D, Stengaard-Pedersen K, Bridal LB et al (2023) Plasma levels of multiple cardiovascular- and inflammation-related proteins analysed for associations with disease activity and anti-cyclic citrullinated peptide status in active early rheumatoid arthritis. Clin Exp Rheumatol 41(9):1801\u20131807. https:\/\/doi.org\/10.55563\/clinexprheumatol\/hrjqdm","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"8488_CR18","doi-asserted-by":"publisher","first-page":"7557","DOI":"10.1007\/s00415-024-12699-1","volume":"271","author":"D Gagliardi","year":"2024","unstructured":"Gagliardi D, Rizzuti M, Masrori P et al (2024) Exploiting the role of Csf nfl, chit1, and mir-181b as potential diagnostic and prognostic biomarkers for Als. J Neurol 271(12):7557\u20137571. https:\/\/doi.org\/10.1007\/s00415-024-12699-1","journal-title":"J Neurol"},{"issue":"1","key":"8488_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW et al (2019) Multiplex proteomics identifies novel Csf and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun 7(1):169. https:\/\/doi.org\/10.1186\/s40478-019-0795-2","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"8488_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49312-y","volume":"15","author":"J Belien","year":"2024","unstructured":"Belien J, Swinnen S, D\u2019Hondt R et al (2024) Chit1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis. Nat Commun 15(1):5013. https:\/\/doi.org\/10.1038\/s41467-024-49312-y","journal-title":"Nat Commun"},{"issue":"4","key":"8488_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ana.25691","volume":"87","author":"E Oldoni","year":"2020","unstructured":"Oldoni E, Smets I, Mallants K et al (2020) Chit1 at diagnosis reflects long-term multiple sclerosis disease activity. Ann Neurol 87(4):633\u2013645. https:\/\/doi.org\/10.1002\/ana.25691","journal-title":"Ann Neurol"},{"issue":"1","key":"8488_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/13510002.2022.2031516","volume":"27","author":"IR Raafat","year":"2022","unstructured":"Raafat IR, Shafik NM, El-Esawy RO et al (2022) The emerging role of Irisin in experimentally induced arthritis: a recent update involving hmgb1\/mcp1\/chitotriosidase i-mediated necroptosis. Redox Rep 27(1):21\u201331. https:\/\/doi.org\/10.1080\/13510002.2022.2031516","journal-title":"Redox Rep"},{"key":"8488_CR23","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.2147\/JIR.S378357","volume":"15","author":"B Dymek","year":"2022","unstructured":"Dymek B, Sklepkiewicz P, Mlacki M et al (2022) Pharmacological Inhibition of Chitotriosidase (chit1) as a novel therapeutic approach for sarcoidosis. J Inflamm Res 15:5621\u20135634. https:\/\/doi.org\/10.2147\/JIR.S378357","journal-title":"J Inflamm Res"},{"issue":"9","key":"8488_CR24","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ et al (2021) Microglial activation and tau propagate jointly across Braak stages. Nat Med 27(9):1592\u20131599. https:\/\/doi.org\/10.1038\/s41591-021-01456-w","journal-title":"Nat Med"},{"key":"8488_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav6221","author":"M Ewers","year":"2019","unstructured":"Ewers M, Franzmeier N, Suarez-Calvet M et al (2019) Increased soluble trem2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer\u2019s disease. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav6221","journal-title":"Sci Transl Med"},{"issue":"12","key":"8488_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1177\/1352458515624558","volume":"22","author":"A Ohrfelt","year":"2016","unstructured":"Ohrfelt A, Axelsson M, Malmestrom C et al (2016) Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler 22(12):1587\u20131595. https:\/\/doi.org\/10.1177\/1352458515624558","journal-title":"Mult Scler"},{"issue":"Pt 11","key":"8488_CR27","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M et al (2008) Identification of soluble trem-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131(Pt 11):3081\u20133091. https:\/\/doi.org\/10.1093\/brain\/awn217","journal-title":"Brain"},{"issue":"2","key":"8488_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jnc.13881","volume":"141","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M et al (2017) Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem 141(2):296\u2013304. https:\/\/doi.org\/10.1111\/jnc.13881","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"8488_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jns.2014.12.016","volume":"348","author":"V Pagliardini","year":"2015","unstructured":"Pagliardini V, Pagliardini S, Corrado L et al (2015) Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci 348(1\u20132):245\u2013250. https:\/\/doi.org\/10.1016\/j.jns.2014.12.016","journal-title":"J Neurol Sci"},{"issue":"1","key":"8488_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jnnp-2018-318868","volume":"90","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Weydt P, Steinacker P et al (2019) Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry 90(1):4\u201310. https:\/\/doi.org\/10.1136\/jnnp-2018-318868","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"8488_CR31","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1136\/jnnp-2018-319586","volume":"90","author":"B Gille","year":"2019","unstructured":"Gille B, De Schaepdryver M, Dedeene L et al (2019) Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 90(12):1338\u20131346. https:\/\/doi.org\/10.1136\/jnnp-2018-319586","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08488-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:40:17Z","timestamp":1764895217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08488-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["8488"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08488-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Research Ethics Committee at Tianjin Medical University General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}